Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%
UP

Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ • Healthcare

$17.73
+$1.03 (+6.2%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$16.76
Day Range$16.69 - $17.79
Avg. Volume (3M)3.8M
Market Cap$1.8B
52 Week Range
$12.73$39.89
Next EarningsIn 84 daysFeb 11, 2027

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$173M100%
Gross Profitminus cost of goods$141M82%

In plain terms: out of every $100 in revenue, Ultragenyx Pharmaceutical Inc. currently loses $68.

Fundamentals & Financials

Revenue (TTM)
$730M
Net Income (TTM)
-$524M
EPS (TTM)
-$5.19
ROA (TTM)
-44.14%
Current Ratio
1.4
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-23.7%Q2 2026-$1.84
+26.2%Q3 2026-$0.9
-5.5%Q4 2026-$1.16
Next

Feb 11

in 84 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -5.5%

Ultragenyx Pharmaceutical’s results missed consensus on both revenue and EPS in the third fiscal quarter of 2026, reported November 3, 2026, even as revenue rose 8.2% to about $173.0 million from roughly $159.9 million a year ago. The top line was led by Product Revenue, which increased 10.5% to about $105.0 million, while Royalty revenue grew 4.6% to roughly $68.0 million. Revenue of $173.0 million trailed the $182.5 million estimate (-5.2%), and EPS of -$1.16 trailed the -$1.10 estimate by -$0.06, improving from -$1.81 a year ago. Profitability remained negative, with gross margin at about 82% and operating margin at roughly -64%, as gross profit came in around $141.0 million and operating income was -$110.0 million. Net income was -$118.0 million, narrowing 34.6% year over year from about -$180.4 million, while operating cash flow was negative at -$43.0 million. For the next period, consensus calls for EPS of -$0.74 on revenue of $226.4 million.

View full earnings history

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for rare and ultra-rare genetic diseases and trades on the NASDAQ under the ticker RARE. The company operates in biotechnology within the healthcare sector, sells marketed biologic products, and generated $673.0 million of revenue in FY2025.

Name
Ultragenyx Pharmaceutical Inc.
CEO
Emil D. Kakkis
Industry
Healthcare
Year Founded
2010
Employees
1,371

Today's Snapshot

AI-generated

RARE closed 6.2% above yesterday's close, outperforming a weaker sector. Ultragenyx gained momentum from the MHRA, Britain’s medicines regulator, over its drug pipeline.

Trading Volume

Above 10d avg 4.1M

4.9M

vs S&P 500 Today

Strong Outperformance

+6.43%

Updated: November 18, 2026 at 21:22 UTC

Technical Indicators

4 Buy2 Neutral2 Sell
RARE presents a mixed but overall constructive short-term setup led by positive momentum and volume. CCI and MACD show buying pressure and price sits above the short- and medium-term moving averages, while on‑balance volume is supportive of recent gains. However, the longer-term averages remain above the price and ADX signals only a weak trend, so momentum is more short-lived than structural. Volatility is moderate and the classic pivot provides nearby support. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$16.32 - $21.73
    Buy
  • RSI (14)60.24
    Neutral
  • Stochastic %K (14, 3, 3)63.56
    Neutral
  • MACD Level (12, 26)0.17
    Buy
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.